Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-08-09 DOI:10.1016/j.medj.2024.06.011

Lee-Ling Lim, Kamlesh Khunti

引用次数: 0

Abstract

The STEP-HFpEF DM trial¹ showed that semaglutide improved body weight, systemic inflammation, and heart failure symptoms in people with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. By addressing both metabolic and cardiovascular risk, semaglutide is a promising therapeutic option for HFpEF in addition to SGLT2i.

查看原文本刊更多论文

高频血栓栓塞治疗：为肥胖症和糖尿病患者带来新希望。

STEP-HFpEF DM 试验1 表明，对于患有肥胖相关性射血分数保留型心力衰竭（HFpEF）和 2 型糖尿病的患者，semaglutide 可改善他们的体重、全身炎症和心力衰竭症状。通过同时解决代谢和心血管风险问题，除了 SGLT2i 之外，semaglutide 还是治疗 HFpEF 的一种很有前景的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.